EB
SPRY icon

Eastern Bank’s ARS Pharmaceuticals SPRY Stock Holding History

Eastern Bank’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-750
Closed -$6.02K – 1168
2026
Q1 		$6.02K Hold
750
– – ﹤0.01% 918
2025
Q4 		$8.74K Buy
+750
New +$7.29K ﹤0.01% 899

Other funds holding SPRY

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
NFGCM
Norman Fields Gottscho Capital Management New York $330M AUM 27.75% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.46B AUM 21.89% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

Eastern Bank's SPRY Position: Q2 2026 in Review

Eastern Bank sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 750 shares — an estimated $6.02K sold.

Eastern Bank first reported a position in SPRY in Q4 2025 and held it in 2 quarters. The position peaked at $8.74K in Q4 2025. 6 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Eastern Bank reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Eastern Bank sold 750 ARS Pharmaceuticals shares in Q2 2026, an estimated $6.02K.
  • Eastern Bank first reported a position in ARS Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Eastern Bank's ARS Pharmaceuticals position peaked at $8.74K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Eastern Bank's 13F filing for Q2 2026, filed 1 Jul 2026.